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Over the past years, cardiovascular magnetic resonance (CMR) has proven its efficacy in large clinical trials, and consequently, the assessment
of function, viability, and ischaemia by CMR is now an integrated part of the diagnostic armamentarium in cardiology. By combining these
CMR applications, coronary artery disease (CAD) can be detected in its early stages and this allows for interventions with the goal to
reduce complications of CAD such as infarcts and subsequently chronic heart failure (CHF). As the CMR examinations are robust and repro-
ducible and do not expose patients to radiation, they are ideally suited for repetitive studies without harm to the patients. Since CAD is a
chronic disease, the option to monitor CAD regularly by CMR over many decades is highly valuable. Cardiovascular magnetic resonance also
progressed recently in the setting of acute coronary syndromes. In this situation, CMR allows for important differential diagnoses. Cardio-
vascular magnetic resonance also delineates precisely the different tissue components in acute myocardial infarction such as necrosis, micro-
vascular obstruction (MVO), haemorrhage, and oedema, i.e. area at risk. With these features, CMR might also become the preferred tool to
investigate novel treatment strategies in clinical research. Finally, in CHF patients, the versatility of CMR to assess function, flow, perfusion,
and viability and to characterize tissue is helpful to narrow the differential diagnosis and to monitor treatment.
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Introduction
The prevalence for coronary artery disease (CAD) in industrialized
countries is high and is estimated to range between 20 000 and
40 000 individuals per million suffering from angina in Europe.1
From large statistics in USA, it is also evident that many patients
with CAD do not experience angina pectoris before their first
heart attack and this fraction is ranging from 50% (for men) up
to 67% (in women).2 Thus, an estimated 40 000–80 000 individuals
per million are at risk for a heart attack at some time during their
course of CAD. Over the past years, cardiovascular magnetic reson-
ance (CMR) emerged as a powerful technique to assess myocardial
ischaemia and viability, and therefore, it may become an increasingly
used technique to monitor and guide treatment in the different
clinical presentations of CAD. In the chronic phases of CAD, ischae-
mia assessment by CMR may become the key test for risk stratifica-
tion, thereby helping in guiding treatment decisions
(revascularizations). In the acute phases of CAD, i.e. in acute coron-
ary syndromes (ACS), viability assessment is most important and
CMR is expected to play an increasing role in differentiating ACS
from other diseases such as perimyocarditis, Takotsubo cardiomyo-
pathy (CMP), or acute aortic diseases. Finally, in the end-stages of
CAD, i.e. in chronic heart failure (CHF), CMR can contribute to
patient management by assessing ischaemia and viability and also
by excluding or confirming differential diagnoses.
In the first part of this review, we will focus on a potential role of
CMR in the patient population at risk. In the second part, the
review describes the possible contribution and the emerging role
* Corresponding author. Tel: +41 21 314 00 10, Fax: +41 21 314 00 13, Email: jurg.schwitter@chuv.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal (2011) 32, 799–809
doi:10.1093/eurheartj/ehq481
of CMR in the setting of acute chest pain and ACS. Finally, in the
third part, the role of ischaemia and viability imaging by CMR in
CHF is discussed.
Ischaemia detection
A key cardiovascular magnetic resonance
application for the assessment of chronic
chest pain and suspected coronary
artery disease
Perfusion-cardiovascular magnetic resonance
The principle of perfusion-CMR is based on the monitoring of con-
trast medium (CM) wash-in kinetics into the myocardium during a
hyperaemic state (Figure 1). In territories supplied by significantly
stenosed coronary arteries, the wash-in of CM is delayed and this
is depicted as dark zones of tissue during CM first-pass, when utiliz-
ing T1-weighted pulse sequences and Gd-based CM (Table 1).
3–8 As
the CM first-pass lasts about 5–15 s during hyperaemia, perfusion-
CMR is performed during a breath-hold to eliminate respiratory
motion artefacts. To eliminate motion artefacts by cardiac contrac-
tion, the acquisition window should last ,100 ms per slice.
Although a spatial resolution of 1–1.5 mm × 1–1.5 mm is poss-
ible,9 a minimum of 2–3 mm × 2–3 mm is required to minimize
susceptibility artefacts at the blood pool–myocardial interface5,10
(for more details, see Table 2). The read-out type of a pulse
sequence [conventional or parallel imaging, fast gradient echo,
(hybrid)-echo-planar, or steady-state free precession] is of minor
importance as long as spatial and temporal resolutions are achieved
as suggested in Table 2.5 Here, it should be mentioned that a signal
increase of 250–300% (relative to pre-contrast myocardial signal) is
required during hyperaemic first-pass to guarantee adequate diag-
nostic performance.10–12 For an example, see Figure 2.
In comparison with 13NH3-PET as the reference standard, sensi-
tivity and specificity for ischaemia detection by CMR were 91 and
94%, respectively, and for detection of ≥50% diameter stenoses,
sensitivity and specificity were 87 and 85%, respectively [area
under the receiver operator characteristics curve (AUC): 0.91].6
Similar results were obtained in other single-centre studies13–16
(Table 1). For perfusion-CMR, CM doses of 0.10 mmol/kg (or
≥0.075 mmol/kg) are recommended.5,10,12 The largest perfusion-
CMR trial published so far is MR-IMPACT.10 In 18 centres in
Europe and USA, perfusion-CMR detected CAD with an AUC of
0.86 (sensitivity and specificity of 86 and 67%, respectively). In com-
parison with the entire single-photon emission computed tomogra-
phy (SPECT) population, perfusion-CMR performed superior vs.
SPECT (Figure 3). This superiority was also shown for multivessel
disease CAD. Of note, SPECT performance in the MR-IMPACT
was also well comparable with the results of earlier multicentre
SPECT studies, which used conventional X-ray coronary angiogra-
phy as the standard of references reporting sensitivities and specifi-
cities of 77–87 and 36–58%, respectively (Figure 3).17–20 We would
like to mention, that in the MR-IMPACT, no attenuation correction
of SPECT data was performed, which is known to improve speci-
ficity. The diagnostic performance of perfusion-CMR was confirmed
later in the MR-IMPACT II study performed in 33 centres in Europe
and USA.10 For both, perfusion-CMR and stress dobutamine-CMR,
a moderate to high reproducibility could be shown (with interob-
server k values of 0.70–0.7321,22 and 0.59–0.81,21–23 respectively).
Perfusion-CMR performed at 3 T yielded similar results as was
observed for 1.5 T.24 As no multicentre data on 3 T perform-
ance are available to date, for clinical perfusion-CMR, the
Figure 1 A schematic explains the various time points of image acquisition relative to contrast medium administration to assess ischaemia and
necrosis/scar tissue. Red line corresponds to normal non-ischaemic myocardium, blue line the ischaemic myocardium, black line the necrotic
tissue in the acute myocardial infarction (fibrotic tissue in chronic myocardial infarction), and purple line the tissue with microvascular obstruc-
tion (MVO).
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1.5 T equipment is recommended. Similarly, no multicentre data
are available comparing visual analysis with quantitative
approaches (e.g. by using upslope data). For perfusion data
sets acquired with parameters as stated in Table 2, a high
image quality will be obtained and similar diagnostic perform-
ances are likely to be achieved by both visual and quantitative
approaches (Table 1). The relationship of data quality and acqui-
sition strategies is currently under investigation within the Euro-
pean CMR registry.25 Regarding the perfusion protocol, a high
diagnostic performance was reported in several studies by analy-
sis of the hyperaemia data only (Table 1), which favours a
stress-only protocol.6,9– 12 Adenosine induces maximal hyperae-
mia at 0.14 mg/min/kg body weight (administered i.v. over
3 min), is characterized by a short half-life (,10 s), and is safe
(1 infarction in .9000 examinations, no death),26,27 and there-
fore, it is currently one of the most commonly used agents in
pharmacological stress testing. A novel selective A2A agonist
regadenoson received approval for pharmacological stress
testing in the USA and is likely to be available in Europe
soon. This novel drug class is easier to use (e.g. injected as a
single bolus); first reports demonstrate a high safety profile,
and similar diagnostic accuracy was achieved as with convention-
al vasodilators when combined with scintigraphy.28
Stress dobutamine-cardiovascular magnetic resonance
A powerful alternative to perfusion-CMR is stress dobutamine-
CMR which detects ischaemia by monitoring regional wall
motion during infusion of increasing doses of dobutamine. This
principle is identical to stress echocardiography, but the CMR
technique benefits from consistently good to high image quality
in a very high percentage of patients. In a landmark paper, dobuta-
mine-CMR performed better than stress echocardiography, where
the difference in diagnostic performance was particularly evident in
patients with reduced echo quality.29 Since then, a large number of
studies demonstrated the high sensitivity and specificity of dobuta-
mine-CMR to detect CAD (Table 1).23,30–34 The CMR protocol is
well established,5 the inotropic stimulation by dobutamine is fol-
lowing mainly that for stress echocardiography (see also Table 2),
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Table 1 Perfusion-cardiovascular magnetic resonance and stress dobutamine-cardiovascular magnetic resonance:
diagnostic performance
Study n (n) Reference CM type/dose Stress Analysis Sensitivity Specificity AUC
Perfusion-CMR
Single6 57 CXA (≥50%) Gd-DTPA-BMA/0.1 mmol/kg Dip (stress only) Upslope
subendo
87 85 0.91
Single6 43 PET (CFR) Gd-DTPA-BMA/0.1 mmol/kg Dip (stress only) Upslope
subendo
91 94 0.93
Single7 92 CXA (≥70%) Gd-DTPA/0.05 mmol/kg Adeno (rest/stress) Upslope PRI 88 82 0.91
Single8 79 CXA (≥50%) Gd-BOPTA/0.05 mmol//kg Adeno (stress/rest) Visual 91 62 —
Single14 84 CXA (≥75%)a Gd-DTPA/0.025 mmol/kg Adeno (rest/stress) Upslope PRI 86 87 0.92
Single15 104 CXA (≥70%) Gd-DTPA/0.75 mmol/kg Dip (stress/rest) Visual 90 85 0.90
Single9 51 CXA (≥50%) Gadobutrol/0.1 mmol/kg Adeno (stress only) Visual — — 0.85
Multicentre16 50 CXA (≥50%) Gd-DTPA/0.05 mmol/kg ATP (stress/rest) Visual 86 75 0.88
Multicentre12 80 (24) CXA (≥50%) Gd-DTPA-BMA/0.1 mmol/kg Adeno (stress only) Upslope
subendo
91 78 0.91
Low dose12 80 (29) CXA (≥50%) Gd-DTPA-BMA/0.05 mmol/kg Adeno (stress only) Upslope
subendo
— — 0.53
MR-IMPACT10 212 (42) CXA (≥50%) Gd-DTPA-BMA/
0.075 mmol/kg
Adeno (stress only) Visual 85 67 0.86
Stress dobutamine-CMR
Single29 186 CXA (≥50%) — Dobutamine Visual 86 86 —
Single30 41b CXA (≥50%) — Dobutamine Visual 83 83 —
Single31 22 CXA (≥75%)a — Dobutamine Visual 88 83 —
Single32 27 CXA (≥70%) — Treadmill Visual 79 85 —
Single8 79 CXA (≥50%) — Dobutamine Visual 89 80 —
Single23c 150 CXA (≥50%) — Dobutamine Visual 78 87 —
Single33 40 CXA (≥50%) — Dobutamine Visual 89 75 —
Single34 204d CXA (≥70%) — Dobutamine Visual 85 86 —
n: in CM dose-finding studies (n) indicates participants in a specific dose group; PRI, perfusion reserve index.
aArea stenosis.
bPatients with negative dobutamine-CMR: CXA was not performed, but a follow-up of 6 months, where no cardiac death occurred.
cReproducibility study: for sensitivity and specificity, means are given.
dWomen only.
Assessment of cardiac ischaemia and viability 801
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cardiovascular magnetic resonance applications
MR modality Types of diagnoses possible Parameters Time
Localizer images Aortic dissection fGRE sequences or SSFP sequences 1–2 min
Aortic aneurysm
Pleural effusion fGRE with and without fat saturation (to detect or exclude fatty
infiltration in ARVC)
Large pneumonia
Intrathoracic masses
Congenital heart diseases
ARVC
Cine CMR Global LV or RV function abnormalities Spatial resolution: 1–2 mm × 1–2 mm 5–10 min
Regional wall motion abnormalities Temporal resolution: 40–60 ms
Hypertrophic cardiomyopathy Preferred sequence type: SSFP
LV aneurysms Slice thickness: 6–10 mm, gap 0–2 mm
Pericardial effusion
Valve abnormalities (valve orifice)
Congenital heart diseases
Stress perfusion-CMR Ischaemia detection Spatial resolution: at least 2–3 mm × 2–3 mm to minimize
susceptibility artefacts along the blood pool–myocardial interface
10 min
Hyperaemia Stress induced perfusion deficit
(adenosine, dipyridamole)
Temporal resolution: 1 short-axis stack/1–2 beats
Adenosine: 0.14 mg/kg/min for 3 min Stress induced segmental dysfunction
(cine CMR with dobutamine)
Acquisition window/slice: ,100 ms to minimize cardiac motion
artefacts
Dipyridamole: 0.56 mg/kg for 4 min Detection of CAD Signal increase during first-pass: .250–300%
CM: 0.075–0.10 mmol/kg injected at 5 mL/s into cubital vein Work-up of patients with known
CAD for treatment decisions
908-preparation delay time: 100–150 ms/slice
Work-up of patients after CABG Coverage: ≥3 short-axis slices
Risk stratification in CAD Slice thickness of 8–10 mm
Stress dobutamine-CMR Sequence: see cine CMR 10–20 min
Dobutamine doses of 10/20/30/40 mg/kg (for 3 min each). Atropine
up to 2 mg is added, if target heart rate (220-age) is not reached
3 short-axis and 3 long-axis acquisitions per dose of dobutamine
Rest perfusion Rest myocardial ischaemia/abnormal
perfusion
Sequence: see stress perfusion-CMR 1 min
Microvascular obstruction
Tumour (differentiation vs. thrombus)
Early gadolinium enhancement Microvascular obstruction Pulse sequences: see LGE 1–10 min
No reflow phenomenon
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Late gadolinium enhancement (LGE) MI Spatial resolution: 1.5–2.0 mm × 1.5–2.0 mm 5–15 min
Myocardial fibrosis Preferred sequence type: segmented inversion recovery (IR) fGRE
Myocarditis Slice thickness: 5–8 mm, gap 0–4 mm
Various non-ischaemic
cardiomyopathies
CM: 0.15–0.2 mmol/kg i.v.
Thrombus Start of imaging: 10–20 min after CM injection
Amyloidosis
T2-weighted CMR Ischaemic area at risk Preferred sequence type: segmented fast spin echo (with double
inversion: dark blood) or STIR
5 min
Myocardial oedema due to inflammation
Intramyocardial haemorrhage (in AMI)
Myocarditis
Takotsubo In progress: T2-prepared single-shot SSFP for T2 maps
Differentiation of acute vs. old infarction
MR angiography Aortic dissection 3D acquisition during breath-hold, typically untriggered 10 min
Aortic aneurysm Spatial resolution: 1–2.5 mm × 1–2.5 mm
Pulmonary embolus CM: 0.1–0.2 mmol/kg at 2–3 mL/s i.v.
Congenital heart diseases
MR coronary angiography Coronary anomalies Free-breathing T2-prep. 3D navigator-gated fGRE 20–30 min
Coronary stenosis (sometimes) Spatial resolution: 1 mm × 1 mm × 1.5 mm
Breath-hold technique for proximal coronaries
CMR flow Insufficient (stenotic) valves Spatial resolution: .8 pixels per vessel diameter 2–5 min
Shunts Velocity encoding 120% of expected peak vel.
Congenital heart diseases
T2*-weighted CMR Iron overload, e.g. in thalassaemia Spoiled gradient multi-echo T2* sequence (normal myocardial
T2*. 20 ms)
2–5 min
Intramyocardial haemorrhage (in AMI)
CMR provides a multimodal integrated assessment of patients with suspected CAD, possible or definite ACS, and CHF. Selection of different imaging modalities should be customized to the likely diagnoses and individualized to a given patient.
Time estimates are rough estimates. ARVC, arrhythmogenic right ventricular cardiomyopathy; CABG, coronary artery bypass grafting; CM, contrast medium; fGRE, fast gradient echo; SSFP, steady-state free precession.
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and it is safe.35 The consistently high image quality is also reflected
by an excellent reproducibility of this test.21,23
Over the last few years, also outcome data after stress
dobutamine-CMR could be collected demonstrating a very low
event rate in patients without ischaemia,36 and this result was
later confirmed by other groups (Figure 4).22 In a study compar-
ing perfusion-CMR with stress dobutamine-CMR, a predictive
value for major adverse cardiac events (MACE) was similar for
both techniques indicating that both ischaemia tests might be
similar in performance.22
Complication management vs. risk
management: the pivotal role
of ischaemia detection
Up to now, cardiologists typically concentrated on symptomatic
patients and treatment was aimed to alleviate angina or to
Figure 4 Prediction of cardiac death and non-fatal myocardial
infarction by assessment of ischaemia in seven large studies com-
prising more than 20 000 patients. In patients without ischaemia,
outcome is excellent.
Figure 2 Example of a 70-year-old female patient with atypical chest pain and mild dyspnoea during exercise. Risk factors were hypercho-
lesterolaemia and diabetes. The patient performed at 100% of predicted workload without symptoms and with a normal stress electrocardio-
gram (mildly ascending 0.07 mV ST depression) and without arrhythmias. Perfusion-cardiovascular magnetic resonance detects severe ischaemia
in all vascular territories. Coronary angiography confirmed a triple-vessel disease and the patient was treated successfully by multiple stenting.
Figure 3 Diagnostic performance of perfusion-cardiovascular
magnetic resonance to detect coronary artery disease (defined
as ≥50% stenosis in invasive coronary angiography) in compari-
son vs. SPECT. Performance of SPECT in MR-IMPACT is compar-
able to those of previous multicentre SPECT trials (given as
squares and circles) reported by Zaret et al.,20 Van Train
et al.,18 and Hendel et al.17 Better performance is obtained with
perfusion-cardiovascular magnetic resonance vs. SPECT
[P, 0.013, in multivessel disease (MVD) P, 0.006]. Modified
from Schwitter et al.10 with permission of Oxford Press.
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manage acute myocardial infarction (AMI) in order to reduce
infarct size and to avoid cardiac death. This paradigm therefore
is based on the management of complications of CAD.
However, the treatment of complications of CAD such as AMI
and sudden cardiac death is not always successful and it is costly.
With the advent of percutaneous coronary interventions (PCI) in
AMI, the death rate of AMI could be reduced in in-hospital
patients, but it remains still high during the outpatient phase of
AMI which underlines the need for early CAD detection.2 As a
consequence, the paradigm of a ‘complications management’, i.e.
to treat symptomatic patients and AMI, should evolve into a ‘risk
management’ approach, which focus on early detection of CAD
and consequently on treatment and revascularization of (sympto-
matic or asymptomatic) CAD to prevent infarctions.37 Updated
guidelines therefore recommend to assess risk not only based on
symptoms, but also on gender and risk factors, as well, and to
revascularize based on the extent and severity of ischaemia.38
High-risk patients should proceed to invasive angiography directly,
whereas intermediate-risk patients with a likelihood for obstructive
CAD of 20–80% (or 10–90%) should undergo ischaemia testing.
In patients without ST-segment changes in the resting electrocar-
diogram (ECG) and which can exercise adequately, a stress ECG
is still the first-line method to use.38 Intermediate-risk patients
post-exercise5,39 are then candidates for non-invasive imaging
tests such as SPECT, stress echocardiography, perfusion-CMR, or
stress dobutamine-CMR to confirm or exclude ischaemia.38
Figure 4 illustrates the prediction of cardiac death and non-fatal
MI by non-invasive ischaemia detection compiled from seven
large studies in more than 20 000 patients.22,36,40– 44 The evidence
for the prognostic value of SPECT40– 43 is large, and a few studies
are available for CMR as well.22,36,44 These large-scale data given in
Figure 4 demonstrate that in patients without ischaemia, compli-
cation rates are very low, justifying a conservative approach focus-
ing on risk factor management.
How does this statement relate to the theory that often non-
obstructive plaques are vulnerable? Here, it appears important to
note that not all plaque ruptures result in infarctions.45,46 The
repeated rupture of vulnerable plaques is most likely the mechan-
ism of disease progression, whereas plaque rupture with consequent
vessel occlusion is the event that directly drives outcome (such as
cardiac death and non-fatal MI).45– 47 As can be seen in Figure 4,
ischaemic patients with haemodynamically relevant plaques are at
a particularly high risk for infarctions, i.e. for plaque ruptures that
cause acute vessel occlusions. Also, an invasive study in more
than 4000 patients with stenosis of ,50% diameter reduction
yielded an event rate for cardiac death/non-fatal MI as low as
1.1%/year,48 whereas an increasing degree of stenosis on invasive
coronary angiography was associated with an increasing risk for
infarctions.49,50 These data and particularly those from non-
invasive imaging (Figure 4) clearly confirm that ischaemia (i.e. its
extent and severity) is a most powerful predictor for future infarc-
tions,22,36,41–44,51 and ischaemia detection takes a central position
in the current guidelines.38,52
Since CAD is a chronic disease with relatively stable phases that
can be interrupted by episodes of disease progression (plaque rup-
tures) and complications (plaque ruptures with occlusions), the
monitoring of disease activity requires a test, which can be
repeated whenever a disease progression is suspected. Cardiovas-
cular magnetic resonance can be repeated theoretically whenever
needed since it is not exposing patients to any ionizing radiation.
This is an important advantage of CMR over SPECT or multidetec-
tor computed tomography (MDCT). Perfusion assessment by
CMR requires one CM administration during hyperaemia, which
results in short examination times of ,1 h. In addition, per-
fusion-CMR is not hindered by stents in the coronary arteries,
so that patients can be monitored after PCI. As PCI are associated
with X-ray exposures, and most patients will also need other
X-ray-based examinations during their life time, it is most reason-
able to avoid X-ray exposure in these patients whenever poss-
ible.53,54 Cardiovascular magnetic resonance is entering now the
routine work-up of patients as shown in the European CMR regis-
try data with .11 000 patients included, where CMR findings
changed diagnosis and consequently further work-up and/or treat-
ment in 60% of the cases.55
Viability assessment
Although a successful risk management strategy should avoid MI,
this concept will not always prevent CAD complications, and as
a consequence, viability assessment will then be required.
Cardiovascular magnetic resonance
applications in ST-segment elevation
myocardial infarction: impact on clinical
management and on research
The diagnosis and management of ST-segment elevation myocar-
dial infarction (STEMI) is well established,56 and in general, there
is no routine need for non-invasive imaging in STEMI during early
phases of presentation, except, for example, in suspected aortic
dissection, where echocardiography, CT, or CMR is required.
Echocardiography is also helpful in suspected cardiac tamponade
or mechanical complications of AMI and CMR is also valuable in
detecting intracardiac thrombus complicating AMI (Figure 5).
Since CMR is an excellent tool for tissue characterization, it
offers unique applications in the field of AMI and, in particular, in
AMI research. Necrosis can be visualized by CMR with excellent
contrast and with submillimetre resolution allowing for detection
of microinfarcts well below 1 g of mass.57,58 This late gadolinium
enhancement (LGE) technique59 is now widely accepted as an
excellent way to assess viability in both acute and chronic MI.
The current-generation gadolinium-based CM (with one excep-
tion) are described as extracellular agents. This means that the
gadolinium chelates rapidly distribute within the intravascular and
interstitial space but are excluded from the intracellular space
(Figures 1 and 6). Because the cell membranes of infarcted myocar-
dium can no longer exclude the contrast from the intracellular
space, over the course of 10–20 min, acutely infarcted myocar-
dium enhances to a much greater extent than viable myocardium
(Figures 1 and 6A and C ).60,61 Thus, LGE imaging quantifies the
extent and severity of myocardial injury after acute reperfused
infarction.60,62–65 Recently, phase-sensitive strategies for LGE
imaging were introduced (phase-sensitive inversion recovery)
that further improved the robustness of CMR viability imaging. In
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large infarcts, particularly when non-reperfused, microvascular
obstruction (MVO) is visualized by the LGE approach as a dark
core residing within a bright infarct zone.66– 68
Several studies have validated LGE vs. biomarker release such as
CK, CKMB, and troponin in the setting of acute or subacute
MI.57,67,69,70 The amount of LGE is inversely related to the eventual
left ventricular (LV) ejection fraction and the transmural extent of
infarction predicts the likelihood of recovery of regional wall
motion (Figure 5). Comparative studies with SPECT58,71 and
PET72–74 suggest significant advantages for CMR due to the
Figure 6 Tissue characterization by cardiovascular magnetic resonance. On the left-hand side (A and C ), late gadolinium enhancement is
applied to delineate tissue necrosis as bright areas (red arrows). In the canine experiment, a small subendocardial necrosis is detected,
whereas in the patient with acute myocardial infarction (C), a dark core in the centre of necrosis is indicating the presence of microvascular
obstruction. On the right, T2-weighted images show increased signal in the myocardium, indicating the presence of oedema, which corresponds
to the area at risk. In the patient (D), dark areas in the centre of oedematous tissue indicate haemorrhage. The oedematous tissue [bright on
T2-weighted images in (B) and (D)], i.e. the area at risk minus the necrotic tissue [in (A) and (C), respectively] yields the amount of salvaged
myocardium.
Figure 5 Viability assessment by late gadolinium enhancement (A) demonstrates the absence of necrosis (lack of bright tissue) in the
hypo-akinetic anterior wall [end-systolic image in (B)]. As expected, the follow-up assessment by cardiovascular magnetic resonance demon-
strates a major recovery of contractile function in the anterior wall [(C) end-systolic images at follow-up]. The late gadolinium enhancement
technique is also sensitive for detection of thrombus, which is attached to a small necrotic (¼bright) area in the apex of the left ventricle (A).
J. Schwitter and A.E. Arai806
increased spatial resolution of CMR compared with nuclear
methods. Furthermore, LGE has excellent sensitivity and specificity
even in the difficult setting of multicentre trials.75,76
Thus, in the field of AMI research, CMR is becoming increasingly
important as it allows for accurate and reproducible quantification
of global and regional LV function, and also for the quantification of
necrosis/scar tissue and MVO (Table 2 and Figure 6). Recently, an
elegant approach was proposed to assess the amount of myocar-
dium at risk. By means of T2-weighted CMR, Aletras et al.
77
demonstrated a close relationship between the amount of tissue
oedema in the myocardium and the area at risk as assessed by
microspheres (Figure 6A and B). Novel pulse sequences are avail-
able now to increase the robustness of T2-weighted oedema
imaging by means of T2 maps.
78 By subtracting necrotic tissue
from the tissue at risk, a myocardial salvage index can be calcu-
lated, which was successfully applied to demonstrate that the
amount of salvaged myocardium in AMI patients is inversely
related to the time delay from pain onset to PCI.79 This index
was also shown to predict MACE.80 Another type of tissue
injury, intramyocardial haemorrhage, can be visualized. Haemor-
rhage influences the T2 properties of tissue and consequently
low signal areas on T2-weighted images were shown to correspond
to haemorrhage on histology.81,82 An example is given in Figure 6D.
A heterogeneous distribution of the various degradation
products of haemoglobin also modify local magnetic field proper-
ties and T2*-weighted sequences might be even more sensitive for
the quantification of haemorrhage.83 The presence of haemor-
rhage in the core of the infarcted area might influence the
healing processes and Ganame et al.84 could observe an adverse
remodelling of the LV in patients after PCI, when haemorrhage
was present in the infarct core.
Cardiovascular magnetic resonance in
acute chest pain patients and in acute
coronary syndromes
Although STEMI diagnosis is straightforward in emergency depart-
ments (ED), a relatively small fraction, typically ,10%, of the
patients with chest pain actually have STEMI and/or an ischaemic
ECG and the great majority does not have ACS.85 Thus, the ED
physician is faced with a daunting task of separating life-threatening
diseases such as ACS, aortic dissection, and pulmonary embolism
from other aetiologies that might not require immediate hospital-
ization. In acute chest pain, the ACCF/AHA Guidelines on ACS86
recommend a non-invasive approach in patients with severe
co-morbidities and in those with a low likelihood for ACS. Simi-
larly, the ESC guidelines recommend non-invasive imaging in
acute chest pain with repetitive negative troponins and normal
or undetermined ECGs.87 As shown in Figure 7, non-invasive
imaging can improve sensitivity of detecting unstable angina/non-
STEMI (NSTEMI) and other causes of chest pain. The first major
clinical trial assessing the diagnostic performance of CMR in the
ED (in patients with 30 min of chest pain and no ST elevation)
detected MI with a sensitivity and specificity of 100 and 79%,
respectively, and many of those false-positive cases turned out
to have unstable angina.88 The primary endpoints, NSTEMI and
unstable angina, were detected by CMR with a sensitivity of 84%
and a specificity of 85%. Cury et al.89 incorporated T2-weighted
imaging into the protocol to differentiate acute from chronic
wall motion abnormalities, which improved the overall results to
a sensitivity of 85% and a specificity of 96%.
Ingkanisorn et al. studied 135 patients with acute chest pain who
had MI excluded by serial ECG and troponin-I. In these patients,
adenosine perfusion-CMR, performed within 72 h of presentation,
yielded the highest sensitivity and specificity (100 and 93%,
respectively) of any single CMR protocol component.90 In addition,
no patients with a negative CMR scan had any cardiovascular out-
comes in a 1-year follow-up. A large percentage of patients with an
abnormal perfusion-CMR had the diagnosis confirmed by other
testing, required revascularization, or suffered from an MI during
follow-up. Plein et al.91 studied NSTE-ACS and adenosine per-
fusion-CMR, performed within 72 h of presentation, yielded the
highest sensitivity and specificity for significant coronary stenosis
detection of 88 and 83%, respectively, which increased to 96 and
83%, respectively, by using images of diagnostic quality only.
Recently, CMR was shown to reduce the overall cost of evaluating
patients with intermediate-risk chest pain.92
With regard to feasibility of using CMR in the ED setting, in the
study by Kwong et al.,88 a total of 11% were excluded (5% because
of claustrophobia). Weight and body size are not significant limit-
ations in centres with high-performance wide-bore scanners.
There remain other significant barriers to the use of CMR in the
routine assessment of chest pain in the ED including limited
ability to accommodate emergency studies, limited availability of
infrastructure needed to perform the relatively complex cardiac
CMR scans, and limited availability of experienced technologists
and physicians.
Figure 7 Performance of different imaging techniques to
detect acute coronary syndromes in acute chest pain patients.
Data are derived for cardiovascular magnetic resonance from
references,88–91 for computed tomographic angiography from
references,106– 111 and for SPECT from references.103,112 –118
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Differential diagnoses of acute
coronary syndromes
Cardiovascular magnetic resonance is very useful to exclude or
confirm conditions that can mimic NSTE-ACS or unstable angina. In
these patients with chest pain and troponin elevations, but normal
coronary angiography, CMR could yield findings typical for myocar-
ditis in 30–50% of the cases.93–95 In Takotsubo CMP characterized
by anginal symptoms, ECG changes, and normal coronary anatomy,
echocardiography or CMR can demonstrate the typical akinetic or
dyskinetic motion of the apex. In addition, in Takotsubo CMP, the
LGE technique can demonstrate tissue viability and exclude myocar-
ditis, which consequently predicts the well-preserved prognosis in
these Takotsubo patients.96–98 In addition, oedema formation was
found in these patients by T2-weighted CMR imaging.
99
Finally, CMR can be applied to detect or exclude acute diseases
of the aorta such as dissection, penetrating ulcers, or intramural
hematoma.5,100 However, it should be mentioned that CT is the
primary method for the assessment of acute diseases of the
aorta or for the ‘triple-rule-out’ strategy due to its speed and
the ease of utilization.
In patients with acute chest pain, echocardiography can detect
regional wall motion abnormalities and, when combined with
CM, can detect perfusion abnormalities. The sensitivity of wall
motion abnormalities in patients with AMI range from 88 to 92%
which is generally lower than thresholds desired by ED
physicians.101,102
Single-photon emission computed tomography imaging can also
be used to evaluate patients with chest pain syndromes in the ED.
Multicentre clinical trials support the conclusion that SPECT
imaging adds a diagnostic value above clinical evaluation103 and
reduce the cost of evaluation compared with short hospitalizations
to evaluate low-risk patients.104 At the same time, these studies
also document the imperfect sensitivity for short-term cardiac
events defined as emergency revascularization, MI, or
death.103,104 Even in a relatively low-risk population, SPECT
missed 3% of AMI in the ED.
Multiple MDCT angiography studies have shown sensitivities and
specificities for CAD detection that exceeds generally accepted
statistics for any of the stress test modalities.105 Although studies
that used MDCT angiography to evaluate patients with acute
chest pain reported a sensitivity of 90–100% and a specificity of
86–96%,106 –110 certain limitations need to be considered. When
non-diagnostic scans are taken into account, sensitivities in some
of these studies may result as low as 57–77%.107,108
Overall, the diagnostic performance of CMR88 –91 to detect ACS
in the ED (Figure 7) is comparable to that of MDCT angiogra-
phy106 –111 or SPECT,103,112 – 118 even though comparative studies
are lacking.
Congestive heart failure
Chronic heart failure in the setting
of ischaemic heart disease
Patients after ACS or AMI are at increased risk for future cardiac
events, and thus, ischaemia testing is reasonable to perform, for
example, by utilization of perfusion-CMR or stress dobutamine-
CMR or any other established ischaemia test, and ischaemia
testing should be combined with a viability assessment. Since the
collagen scar has relatively little intracellular space and a large
interstitial space, the volume of distribution of gadolinium chelate
is much higher than in the normal myocardium, resulting in a
bright scar and viable myocardium appearing nulled or dark
(Figures 1 and 5). In a landmark paper, Kim et al.119 demonstrated
the ability of CMR to predict the recovery of segmental contractile
function post-revascularization in relation to the transmurality of
scar tissue in dysfunctional segments. After revascularization, seg-
ments with ≤25% transmurality of scar recovered function in
about 80%, whereas ,10% of segments recovered when trans-
murality exceeded 50% of wall thickness.119 These results were
confirmed by others.68,71 Another study stressed the finding that
a scar thickness of 4 mm or more is associated with a very
low likelihood of functional recovery due to tethering, whereas a
viable rim of 4 mm is required to allow for recovery of
function.73 In addition to tissue characterization, low-dose
dobutamine-CMR can be performed as well to assess the likeli-
hood of functional recovery. Thus, patients with CHF and substan-
tial hibernating or stunning myocardium can be readily detected by
CMR and benefit from revascularization. Both scar mass120 and
detection of MVO120– 122 predict the outcome. In patients
without MVO, MACE-free survival was 90% at 18 months, but
decreased to 50% in patients with MVO. The presence of
viable and scar tissue was shown to predict responsiveness to
cardiac resynchronization therapy (CRT) using nuclear tech-
niques.123 Novel CMR-based models propose to integrate
viability data into maps of dyssynchrony to predict CRT
responsiveness.124
Cardiovascular magnetic resonance is also very sensitive in
detecting intracardiac thrombi that complicate infarctions in up
to 20–30% of the cases.125 –127 In a comparative study of 361
patients with surgical or pathological confirmation of intracardiac
thrombus, CMR had a better sensitivity for thrombus detection
than transoesophageal and transthoracic echocardiography while
all three modalities had excellent specificities of 99, 96, and 96%,
respectively.126 In another comparative study, contrast echocardio-
graphy nearly doubled sensitivity to detect LV thrombi vs. non-
contrast echocardiography, but was inferior in comparison to
LGE, which was particularly powerful for mural and small apical
thrombi.127
Chronic heart failure in non-ischaemic
heart disease
In CHF, hibernation, stunning, ischaemia, or scar is not always the
substrate of dysfunction. A variety of differential diagnoses exist
and CMR can considerably contribute in this situation, as the
identification of different aetiologies leading to CHF is a prerequi-
site for a targeted CHF treatment. In dilated CMP, typically no
localized endocardial scars are detected, but zones of fibrosis in
the mid-wall of the interventricular septum and at the LV–RV
insertion points are frequently present,128 whereas ischaemia is
absent. Again, in dilative CMP, the amount of LGE is strongly
related to prognosis.93 Another important differential diagnosis
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in CHF to consider is myocarditis. Inflammatory involvement of
the myocardium is in general progressing from the subepicardial
layer towards the endocardium and most frequently locates in
the lateral and inferior walls of the LV.95,129 – 134 If inflammation
results in irreversible myocyte damage, the LGE technique
delineates inflammatory tissue with high spatial resolution allowing
to recognize the typical pattern of lesions and also enables
accurate follow-up studies to assess responsiveness to treatment.
T2-weighted non-contrast- and T1-weighted contrast-enhanced
CMR sequences, which are sensitive for tissue oedema, may add
additional diagnostic information.135,136 Cardiac amyloidosis is
another entity that can cause CHF. Conventional gadolinium-based
CM exhibit a high affinity to the amyloid material, which results in
specific CM kinetics. These CM kinetics can easily be assessed by
the LGE technique137,138 and yield sensitivities and specificities for
the diagnosis of cardiac amyloidosis of 80 and 94%, respectively.139
Cardiovascular magnetic resonance applications are helpful in
the differential diagnosis of many other cardiac diseases that can
lead to CHF.5 Although many of them cannot be mentioned
here, it is worthwhile to recognize that iron overload, e.g. in tha-
lassaemia patients, is the most frequent reason causing death in
this large population. Cardiovascular magnetic resonance T*2
measurements can be applied in a few breath-holds and are now
generally accepted as the method of choice to guide chelation
therapy as this approach could dramatically decrease the global
and cardiac death rate.140,141
Safety aspects of cardiovascular
magnetic resonance
Electronic devices such as pacemakers, defibrillators, infusion
pumps, and others are considered as absolute contraindications.142
There is up to now one pacemaker type which obtained approval
from regulatory authorities to be MR compatible, and other manu-
facturers will certainly follow soon with similar products. Preliminary
experience shows an overall preserved image quality with this
MR-compatible pacemaker with only minimal artefacts along the
leads. In general, implanted devices such as heart valves, occluders,
and stents143 are compatible with MR, at least up to 1.5 T (for
further information, several websites are available for detailed
listing).5 Claustrophobia is present in up to 5% of the cases and the
administration of a tranquilizer is usually very effective.144 Concern-
ing the administration of CM, the cases of nephrogenic systemic
fibrosis (NSF) were described where the skin and in severe cases
also internal organs develop a fibrosis which can lead to death.145
This NSF is documented in some 350146–500145 cases worldwide
for linear gadolinium chelates (out of up to 200 million adminis-
trations), whereas macrocyclic gadolinium chelates are considered
of very low risk (with ,10 unconfounded cases reported so far).
Outlook
As CMR is now entering the clinical arena, it will be crucial to
monitor its performance in daily practice. Also, prognostic data
on CMR are rare. The European Registry on CMR was started
with a pilot in 2008 and is now active in many European countries
and will deliver valuable insights regarding the prognostic yield of
ischaemia and viability CMR.55,58 New CMR techniques are at
the horizon in the field of metabolic imaging using hyperpolarized
13C compounds147,148 and for tissue characterization, detection of
inflammation,149 and cell tracking using fluorine-based CMR.146 In
the future, metabolic CMR and fluorine CMR will be fused with
the ‘conventional’ function, perfusion, and viability CMR infor-
mation in order to study the myocardium in depth.147,149
Conclusions
Cardiovascular magnetic resonance has developed considerably in
the past years, and in particular, function, viability, and ischaemia
imaging are now an integrated part of the diagnostic armamentar-
ium in cardiology. By combining these CMR applications, CAD can
be detected in its early stages and this allows for interventions with
the goal to reduce complications of CAD such as infarcts and, at a
later stage, heart failure. As the CMR examinations are robust and
reproducible and do not expose patients to radiation, they can be
repeated without harm to the patients, which is important as CAD
is a chronic disease and patients therefore should be monitored
over several decades.
Cardiovascular magnetic resonance also progressed recently in
the setting of ACS. In this situation, CMR allows for important
differential diagnoses and it also delineates precisely the different
tissue components in AMI such as necrosis, MVO, haemorrhage,
and oedema, i.e. area at risk. With these advantages, CMR might
become the preferred tool to investigate novel treatment strat-
egies in clinical research.
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